Activity Date: 04/28/2025
Sign in (or create a FREE account) to access this FREE session!Date: Monday, 04/28/2025
Time: 12:30 PM (view in the schedule)
Room: Salt Lake CD-L2
To view the session live, you will need to reload this page closer to when the session starts.
Existing psychotropic nomenclature (e.g., “atypical antipsychotics”) falls quite short of being accurate or useful. Here, Dr. Joseph Goldberg will take a deep dive into the issues with current nomenclature -including the impact on clinician behavior, patient outcomes, and stigma. The evolving proposals for revising psychotropic nomenclature to reflect pharmacology and mechanism will be investigated. Specifically, issues arising from the use of outdated “atypical antipsychotic” and “antidepressant” terminology will be explored as well as the evidence base, approvals, and indications of various psychotropic medication classes in the treatment of mood disorders. After taking part in this educational activity, it is hoped that attendees will become a part of the nomenclature solution by ceasing use of antiquated terms and adopting updated, neuroscience-centered psychotropic nomenclature.
Joseph F. Goldberg, MD
View biographical informationAAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.
